BRÈVE

sur VALBIOTIS (EPA:ALVAL)

Valbiotis Enters Middle East Market with Exclusive Distribution Deal

Graphique de l'évolution du cours de l'action VALBIOTIS (EPA:ALVAL).

Valbiotis, a French laboratory specializing in scientifically tested dietary supplements, announced an exclusive distribution agreement with Mena Nutrition for the Middle East. Mena Nutrition will market Valbiotis products in Saudi Arabia, Lebanon, and Iraq, with first revenues anticipated by late 2026.

Mena Nutrition, based in the UAE, boasts over 20 years of experience and a strong local presence. This strategic partnership aims to position ValbiotisPRO® products as the gold standard in cardiometabolic prevention, leveraging robust scientific support.

Commercialization is slated to begin after necessary health authority registrations are secured in each country. The Middle East markets hold significant potential for Valbiotis due to high prevalence rates of metabolic-related diseases.

This deal marks a key step in Valbiotis' international expansion strategy, emphasizing their commitment to preventive health solutions globally.

R. P.

Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de VALBIOTIS